

jsou hospitalizováni déle než 1 rok. Ukazuje se, že z 2 000 pacientů má asi 20 % pacientů tak závažnou symptomatologii, že potřebují dlouhodobou zdravotní péči a není tedy pravdou, že v psychiatrických zařízeních jsou jen pacienti ze sociálních důvodů.

Profesor Kašpárek sdělil, že tato data máme poměrně recentně a máme možnost s nimi pracovat a říct si, jaká by měla být kapacita jednotlivých prvků péče. Je to program práce pro výbor společnosti a pro ministerstvo pro letošní rok, s cílem nasměrovat zdroje tam, kde jsou potřeba,

jednak aby pacienti dostali péči, když ji potřebují, a aby segmenty, které máme špatně rozvinuté, měly dostatečnou kapacitu a nebyly přetížené. Profesor Kašpárek své sdělení ukončil přáním, aby se nejednalo jenom o reformu na papíře, ale aby se doopravdy podařilo ji zrealizovat.

## LITERATURA

- Levitán B, Markowitz M, Mohamed AF, et al. Patients' Preferences Related to Benefits, Risks, and Formulations of Schizophrenia Treatment. *Psychiatr Serv.* 2015 Jul;66(7):719-26. doi: 10.1176/appi.ps.201400188. Epub 2015 Mar 16. PMID: 25772762.
- Achtyes E, Simmons A, Skabeev A, et al. Patient preferences concerning the efficacy and side-effect profile of schizophrenia medications: a survey of patients living with schizophrenia. *BMC Psychiatry.* 2018 Sep 12;18(1):292. doi: 10.1186/s12888-018-1856-y. PMID: 30223804; PMCID: PMC6142379.
- Meltzer HY, Cucchiari J, Silva R, et al. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study. *Am J Psychiatry.* 2011 Sep;168(9):957-67. doi: 10.1176/appi.ajp.2011.10060907. Epub 2011 Jun 15. PMID: 21676992.
- Stahl SM, Cucchiari J, Simonelli D, et al. Effectiveness of lurasidone for patients with schizophrenia following 6 weeks of acute treatment with lurasidone, olanzapine, or placebo: a 6-month, open-label, extension study. *J Clin Psychiatry.* 2013 May;74(5):507-15. doi: 10.4088/JCP.12m08084. Epub 2013 Mar 13. PMID: 23541189.
- Pillinger T, McCutcheon RA, Vano L, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. *Lancet Psychiatry.* 2020 Jan;7(1):64-77. doi: 10.1016/S2215-0366(19)30416-X. Epub 2019 Dec 17. PMID: 31860457; PMCID: PMC7029416.
- Mattingly GW, Haddad PM, Tocco M, et al. Switching to Lurasidone following 12 months of treatment with Risperidone: results of a 6-month, open-label study. *BMC Psychiatry.* 2020 May 5;20(1):199. doi: 10.1186/s12888-020-02523-1. PMID: 32370778; PMCID: PMC7201608.
- Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. *Lancet.* 2019 Sep 14;394(10202):939-951. doi: 10.1016/S0140-6736(19)31135-3. Epub 2019 Jul 11. Erratum in: *Lancet.* 2019 Sep 14;394(10202):918. PMID: 31303314; PMCID: PMC6891890.
- Abosi O, Lopes S, Schmitz S, Fiedorowicz JG. Cardiometabolic effects of psychotropic medications. *Horm Mol Biol Clin Investig.* 2018 Jan 10;36(1):j/hmbci.2018. 36. issue-1/hmbci-2017-0065/hmbci-2017-0065.xml. doi: 10.1515/hmbci-2017-0065. PMID: 29320364; PMCID: PMC6818518.
- Nicol GE, Kolko R, Lenze EJ, et al. Adiposity, Hepatic Triglyceride, and Carotid Intima Media Thickness During Behavioral Weight Loss Treatment in Antipsychotic-Treated Youth: A Randomized Pilot Study. *J Child Adolesc Psychopharmacol.* 2019 Aug;29(6):439-447. doi: 10.1089/cap.2018.0120. Epub 2019 Apr 17. PMID: 30994376; PMCID: PMC6661918.
- McWhinney S, Kolenic M, Franke K, et al. Obesity as a Risk Factor for Accelerated Brain Ageing in First-Episode Psychosis-A Longitudinal Study. *Schizophr Bull.* 2021 Oct 21;47(6):1772-1781. doi: 10.1093/schbul/sbab064. PMID: 34080013; PMCID: PMC8530396.
- Siafis S, Davis JM, Leucht S. Antipsychotic drugs: from 'major tranquilizers' to Neuroscience-based Nomenclature. *Psychol Med.* 2021 Feb;51(3):522-524. doi: 10.1017/S0033291719003957. Epub 2020 Jan 8. PMID: 31910928.
- Baldez DP, Biazus TB, Rabelo-da-Ponte FD, et al. The effect of antipsychotics on the cognitive performance of individuals with psychotic disorders: Network meta-analyses of randomized controlled trials. *Neurosci Biobehav Rev.* 2021 Jul;126:265-275.
- Harvey PD, Siu CO, Ogasa M, Loebel A. Effect of lurasidone dose on cognition in patients with schizophrenia: post-hoc analysis of a long-term, double-blind continuation study. *Schizophr Res.* 2015 Aug;166(1-3):334-8
- Hagi K, Nosaka T, Dickinson D, et al. Association Between Cardiovascular Risk Factors and Cognitive Impairment in People With Schizophrenia: A Systematic Review and Meta-analysis. *JAMA Psychiatry.* 2021 May 1;78(5):510-518. doi: 10.1001/jamapsychiatry.2021.0015. PMID: 33656533; PMCID: PMC7931134.
- Pochiero I, Calisti F, Comandini A, et al. Impact of Lurasidone and Other Antipsychotics on Body Weight: Real-World, Retrospective, Comparative Study of 15,323 Adults with Schizophrenia. *Int J Gen Med.* 2021 Jul 31;14:4081-4094.
- Stahl SM, Cucchiari J, Simonelli D, et al. Effectiveness of lurasidone for patients with schizophrenia following 6 weeks of acute treatment with lurasidone, olanzapine, or placebo: a 6-month, open-label, extension study. *J Clin Psychiatry.* 2013 May;74(5):507-15.
- Mattingly GW, Haddad PM, Tocco M, et al. Switching to Lurasidone following 12 months of treatment with Risperidone: results of a 6-month, open-label study. *BMC Psychiatry.* 2020 May 5;20(1):199.
- Etchecopar-Etchart D, Korchia T, Loundou A, et al. Comorbid Major Depressive Disorder in Schizophrenia: A Systematic Review and Meta-Analysis. *Schizophr Bull.* 2021 Mar 16;47(2):298-308.
- Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al. Comparative Efficacy and Tolerability of 32 Oral Antipsychotics for the Acute Treatment of Adults With Multi-Episode Schizophrenia: A Systematic Review and Network Meta-Analysis. *Focus (Am Psychiatr Publ).* 2020 Oct;18(4):443-455.
- Gregory A, Mallikarjun P, Upthegrove R. Treatment of depression in schizophrenia: systematic review and meta-analysis. *Br J Psychiatry.* 2017 Oct;211(4):198-204.
- Tiihonen J, Tanskanen A, Taipale H. 20-Year Nationwide Follow-Up Study on Discontinuation of Antipsychotic Treatment in First-Episode Schizophrenia. *Am J Psychiatry.* 2018 Aug 1;175(8):765-773.
- Ostuzzi G, Vita G, Bertolini F, et al. Continuing, reducing, switching, or stopping antipsychotics in individuals with schizophrenia-spectrum disorders who are clinically stable: a systematic review and network meta-analysis. *Lancet Psychiatry.* 2022 Aug;9(8):614-624.
- Liu CC, Takeuchi H. Achieving the Lowest Effective Antipsychotic Dose for Patients with Remitted Psychosis: A Proposed Guided Dose-Reduction Algorithm. *CNS Drugs.* 2020 Feb;34(2):117-126. doi: 10.1007/s40263-019-00682-8. PMID: 31741178.
- Thornicroft G, Tansella M, Antonelli R. The Lancet Mortality in schizophrenia: a meta-analysis. 2005;365(9460):589-599.

## ERRATUM

Omlouváme se za chybné uvedení, že článek MUDr. Jonáše Bočka – Manická epizoda po prodělání covid-19 pneumonie (*Pediatr. praxi.* 2023;24(1):43-45), publikovaný v časopise *Psychiatrie pro praxi* 1/2023, byl zpracován na základě přednášky prof. MUDr. Libora Ustohala, Ph.D. Jedná se o původní článek autora.

Redakce